MS Highlights From the 2017 Annual Neurology Meeting

Slides:

Advertisements

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Advertisements

FREEDOMS II TRIAL.

Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.

RIS CIS CDMS SPMS Long-term disability progression

Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.

Multiple sclerosis: Oral Therapies and Beyond

Introduction to Direct-to-Consumer Genetic Testing

New Horizons for SMA.

The Nurse View.

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Highlights From the 2015 European Multiple Sclerosis Meeting

The Ever-Expanding Patient Pool for TAVR:

Highlights From the 2017 Annual European MS Meeting

Perspectives on Key MS Data From the Annual European MS Meeting

Improving Survival in Glioblastoma Multiforme

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Program Goals Teriflunomide: Pooled Safety Data.

EHRs and HIPAA: Steps to Maintain Privacy and Security of Patient Data

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Applying Real-World Evidence in MS: Reviewing the State of the Art

Emerging Data and Clinical Advances in MS:

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Please consider these data to be preliminary until they have been published in peer-reviewed journals.

T-Cell Directed Therapy in MS

Assessing Disease Progression in MS Treatment

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Novel Therapies for the Treatment of MS

What Is the Role of Injectables in the Modern Era of MS Treatment?

Should I Stay or Should I Go?

Evaluating Next-Generation BTK Inhibitors

Program Goals Disclaimer Overview Assessing Disease Activity.

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Personalized Therapy in Relapsed or Refractory CLL

Treating to Target in MS

New Data on Emerging Treatments for Psoriasis

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Program Goals Overview Is NEDA a Reasonable Target?

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Opportunistic Infections in MS What Is the Risk?

Clinical Pearls on Hot Topics in MS

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Proteasome Inhibitors and Patients

Emerging Multiple Sclerosis Therapies

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Program Goals Overview Is NEDA a Reasonable Target?

Novel Therapeutics in MS

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Third-Generation EGFR TKIs

Mitigating Infection Risk With DMT in MS

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

MS, Age, and Immune Function

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Updates in Progressive MS

Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE) Kyle Smoot, MD, FAAN1, Kiren Kresa-Reahl, MD1, Pavle.

Understanding the Role of Disability in MS Management

Selective Immunomodulation in MS

Translating Data From Trial to Practice

Presentation transcript:

MS Highlights From the 2017 Annual Neurology Meeting

Introduction

JCV-Positive Patients: Switching From Natalizumab

IFNβ-1a tiw Reduces Disease Activity

Ocrelizumab Phase 2 Trial

Ocrelizumab Phase 2 Trial: MRI Results

Conclusions

MS Highlights From the 2017 Annual Neurology Meeting

Spinal Cord Gray Matter Atrophy

Spinal Cord Gray Matter Atrophy (cont)

Vitamin D Polymorphisms and Risk of MS

Vitamin D Polymorphisms and Risk of MS (cont)

Microbiome in Relapsing MS

Reserve in MS

Reserve in MS: Results

Conclusions

MS Highlights From the 2017 Annual Neurology Meeting

Introduction

Defining NEPAD

ORATORIO: Ocrelizumab Reduces Disease Activity

Siponimod Safety

ASCEND: Improvement in Disability?

Conclusions

MS Highlights From the 2017 Annual Neurology Meeting

Opicinumab: SYNERGY Efficacy

Opicinumab: SYNERGY Efficacy (cont)

MIS416 in SPMS

Cladribine: ORACLE-MS Open-Label Maintenance Period

Cladribine Efficacy in High Disease Activity

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)